PERK inhibitors
PERK inhibitors are a class of drugs that inhibit the protein kinase PERK. PERK, or Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase, is a type of enzyme that in humans is encoded by the EIF2AK3 gene. It is involved in the Unfolded Protein Response (UPR), a cellular stress response related to the endoplasmic reticulum.
Mechanism of Action[edit]
PERK inhibitors work by blocking the activity of the PERK enzyme. This enzyme is activated in response to the accumulation of unfolded proteins in the endoplasmic reticulum, a condition known as Endoplasmic Reticulum Stress (ERS). When activated, PERK phosphorylates the eukaryotic initiation factor 2 alpha (eIF2α), leading to a reduction in general protein synthesis but an increase in the translation of specific mRNAs such as ATF4.
By inhibiting PERK, these drugs can potentially modulate the UPR and have therapeutic effects in diseases where ERS and UPR are implicated, such as neurodegenerative diseases, cancer, and diabetes.
Clinical Use[edit]
Currently, PERK inhibitors are primarily used in research settings. However, they have potential therapeutic applications in a variety of diseases. For example, in neurodegenerative diseases like Alzheimer's disease and Parkinson's disease, PERK inhibition has been shown to reduce neuronal death and improve cognitive and motor function in animal models.
In cancer, PERK activation is often associated with tumor survival and growth, and its inhibition can potentially suppress tumor growth. In diabetes, PERK plays a role in beta-cell dysfunction and death, and its inhibition could potentially protect beta cells and improve insulin secretion.
Side Effects[edit]
As with any drug, PERK inhibitors can have side effects. These can include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include liver damage and kidney damage. However, these side effects are generally rare and the drugs are generally well tolerated in research settings.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
